Literature DB >> 17681844

A scientific journey through the 2-5A/RNase L system.

Robert H Silverman1.   

Abstract

The antiviral and antitumor actions of interferons are caused, in part, by a remarkable regulated RNA cleavage pathway known as the 2-5A/RNase L system. 2'-5' linked oligoadenylates (2-5A) are produced from ATP by interferon-inducible synthetases. 2-5A activates pre-existing RNase L, resulting in the cleavage of RNAs within single-stranded regions. Activation of RNase L by 2-5A leads to an antiviral response, although precisely how this happens is a subject of ongoing investigations. Recently, RNase L was identified as the hereditary prostate cancer 1 gene. That finding has led to the discovery of a novel human retrovirus, XMRV. My scientific journey through the 2-5A system recounts some of the highlights of these efforts. Knowledge gained from studies on the 2-5A system could have an impact on development of therapies for important viral pathogens and cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681844      PMCID: PMC2075094          DOI: 10.1016/j.cytogfr.2007.06.012

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  106 in total

1.  Microarray-based detection and genotyping of viral pathogens.

Authors:  David Wang; Laurent Coscoy; Maxine Zylberberg; Pedro C Avila; Homer A Boushey; Don Ganem; Joseph L DeRisi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

2.  Crystal structure of the 2'-specific and double-stranded RNA-activated interferon-induced antiviral protein 2'-5'-oligoadenylate synthetase.

Authors:  Rune Hartmann; Just Justesen; Saumendra N Sarkar; Ganes C Sen; Vivien C Yee
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

3.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.

Authors:  Graham Casey; Phillippa J Neville; Sarah J Plummer; Ying Xiang; Lisa M Krumroy; Eric A Klein; William J Catalona; Nina Nupponen; John D Carpten; Jeffrey M Trent; Robert H Silverman; John S Witte
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

4.  RNase L mediates transient control of the interferon response through modulation of the double-stranded RNA-dependent protein kinase PKR.

Authors:  Khalid S A Khabar; Yunus M Siddiqui; Fahad al-Zoghaibi; Latifa al-Haj; Mohammed Dhalla; Aimin Zhou; Beihua Dong; Mark Whitmore; Jayashree Paranjape; Mohammed N Al-Ahdal; Futwan Al-Mohanna; Bryan R G Williams; Robert H Silverman
Journal:  J Biol Chem       Date:  2003-02-11       Impact factor: 5.157

Review 5.  Implications for RNase L in prostate cancer biology.

Authors:  Robert H Silverman
Journal:  Biochemistry       Date:  2003-02-25       Impact factor: 3.162

6.  Structural and functional genomics and evolutionary relationships in the cluster of genes encoding murine 2',5'-oligoadenylate synthetases.

Authors:  Tomoji Mashimo; Philippe Glaser; Marianne Lucas; Dominique Simon-Chazottes; Pierre Emmanuel Ceccaldi; Xavier Montagutelli; Philippe Desprès; Jean Louis Guénet
Journal:  Genomics       Date:  2003-11       Impact factor: 5.736

7.  An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase.

Authors:  Geqiang Li; Ying Xiang; Kanaga Sabapathy; Robert H Silverman
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

8.  Alphavirus minus-strand synthesis and persistence in mouse embryo fibroblasts derived from mice lacking RNase L and protein kinase R.

Authors:  Dorothea L Sawicki; Robert H Silverman; Bryan R Williams; Stanley G Sawicki
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates.

Authors:  Ying Xiang; Zhengfu Wang; Junko Murakami; Sarah Plummer; Eric A Klein; John D Carpten; Jeffrey M Trent; William B Isaacs; Graham Casey; Robert H Silverman
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

10.  Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer.

Authors:  Sean R Downing; Kristen T Hennessy; Miyako Abe; Judith Manola; Daniel J George; Philip W Kantoff
Journal:  Clin Prostate Cancer       Date:  2003-12
View more
  40 in total

1.  Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

Authors:  Tobias Paprotka; Narasimhan J Venkatachari; Chawaree Chaipan; Ryan Burdick; Krista A Delviks-Frankenberry; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

2.  An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity.

Authors:  Xiao-Ling Li; Heather J Ezelle; Tae-Jin Kang; Lei Zhang; Kari Ann Shirey; Janette Harro; Jeffrey D Hasday; Saroj K Mohapatra; Oswald R Crasta; Stefanie N Vogel; Alan S Cross; Bret A Hassel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 3.  Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and the Safety of the Blood Supply.

Authors:  Andrew D Johnson; Claudia S Cohn
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 4.  Is XMRV a causal virus for prostate cancer?

Authors:  Zhen-Zhen Zhang; Bao-Feng Guo; Zhuang Feng; Ling Zhang; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2011-07-18       Impact factor: 3.285

5.  RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis.

Authors:  Bingbing Wei; Zhuoqun Xu; Jun Ruan; Ming Zhu; Ke Jin; Deqi Zhou; Zhiqiang Yan; Feng Xuan; Hongyi Zhou; Xing Huang; Jian Zhang; Peng Lu; Jianfeng Shao
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

Review 6.  Resveratrol: Biological and pharmaceutical properties as anticancer molecule.

Authors:  Tze-chen Hsieh; Joseph M Wu
Journal:  Biofactors       Date:  2010 Sep-Oct       Impact factor: 6.113

7.  Comparison of antiviral activity of recombinant and natural interferons against crimean-congo hemorrhagic Fever virus.

Authors:  Helen Karlberg; Gunnel Lindegren; Ali Mirazimi
Journal:  Open Virol J       Date:  2010-04-22

8.  Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome.

Authors:  Otto Erlwein; Steve Kaye; Myra O McClure; Jonathan Weber; Gillian Wills; David Collier; Simon Wessely; Anthony Cleare
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

9.  Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients.

Authors:  Oliver Hohn; Hans Krause; Pia Barbarotto; Lars Niederstadt; Nadine Beimforde; Joachim Denner; Kurt Miller; Reinhard Kurth; Norbert Bannert
Journal:  Retrovirology       Date:  2009-10-16       Impact factor: 4.602

10.  RNase L mediated protection from virus induced demyelination.

Authors:  Derek D C Ireland; Stephen A Stohlman; David R Hinton; Parul Kapil; Robert H Silverman; Roscoe A Atkinson; Cornelia C Bergmann
Journal:  PLoS Pathog       Date:  2009-10-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.